caa a22 4500 465789501 CHVBK 20180323112019.0 cr unu---uuuuu 170327e19900801xx s 000 0 eng 10.1007/BF00171838 doi (NATIONALLICENCE)springer-10.1007/BF00171838 Activity of intravenous menogaril in patients with previously untreated metastatic breast cancer [Elektronische Daten] A National Cancer Institute of Canada Clinical Trials Group study [Elizabeth Eisenhauer, Kathleen Pritchard, Daniele Perrault, Shailendra Verma, Joseph Pater] Summary: We have carried out a phase II study of intravenous menogaril given every four weeks in a group of patients with breast cancer who had received no prior chemotherapy for metastatic disease. Myelosuppression, nausea and vomiting and local reactions were seen frequently. Six partial responses (median duration 154 days) were seen in 24 eligible patients. We conclude menogaril is active in breast cancer and recommend that because it can be delivered in high doses orally, future trials in this disease should focus on intense oral schedule. Kluwer Academic Publishers, 1990 menogaril nationallicence breast cancer nationallicence Eisenhauer Elizabeth NCIC Clinical Trials Group, Kingston, Ontario, Canada aut Pritchard Kathleen Women's College Hospital, Toronto, Ontario, Canada aut Perrault Daniele Ottawa Regional Cancer Centre, Ottawa, Ontario, Canada aut Verma Shailendra Ottawa Regional Cancer Centre, Ottawa, Ontario, Canada aut Pater Joseph NCIC Clinical Trials Group, Kingston, Ontario, Canada aut Investigational New Drugs Kluwer Academic Publishers 8/3(1990-08-01), 283-287 0167-6997 8:3<283 1990 8 10637 https://doi.org/10.1007/BF00171838 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00171838 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Eisenhauer Elizabeth NCIC Clinical Trials Group, Kingston, Ontario, Canada aut NATIONALLICENCE 700 1- Pritchard Kathleen Women's College Hospital, Toronto, Ontario, Canada aut NATIONALLICENCE 700 1- Perrault Daniele Ottawa Regional Cancer Centre, Ottawa, Ontario, Canada aut NATIONALLICENCE 700 1- Verma Shailendra Ottawa Regional Cancer Centre, Ottawa, Ontario, Canada aut NATIONALLICENCE 700 1- Pater Joseph NCIC Clinical Trials Group, Kingston, Ontario, Canada aut NATIONALLICENCE 773 0- Investigational New Drugs Kluwer Academic Publishers 8/3(1990-08-01), 283-287 0167-6997 8:3<283 1990 8 10637 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer